cancer

Medline's sterilization facility in Waukegan uses ethylene oxide and that cause cancer. EPA Delayed Risk Communication and Issued Instructions Hindering Region 5’s Ability to Address Ethylene Oxide Emissions (cnn.com)

In an exclusive interview with the AlphaStreet, ImmunoGen Inc (NASDAQ: IMGN) executive chief Mark Enyedy spoke about the company's product strategy, pipeline, and more. The pharma sector continues to be running on the tight budgets due to disruptive COVID-19 pandemic. However, ImmunoGen...

I am hearing that this company might be the next big thing. Anyone?

As the pharmaceutical business continues to contract, with higher sales targets and tighter bonus structures, we look to other means of income to support our personal growth. These opportunities come in different ways, such as lab sales, device sales and marketing gigs. We have seen many...

In a deal aimed at expanding its oncology portfolio further, Eli Lilly will acquire cancer drug maker AurKa Pharma. The decision comes a few days after the pharma giant agreed to buy late-stage immune-oncology company ARMO Biosciences...

Celgene reported better-than-expected first quarter results, as its flagship drug for multiple myeloma continued to increase in new and repeat prescriptions and longer average duration of use. Revenue continued to be benefited from the company’s key growth driver Revlimid, which was approved...

JNJ reported a 12.6% increase in sales to $20 billion for the first quarter of 2018 as domestic sales grew 6.1% and those from international markets improved about 20%. Net earnings fell slightly to $4.4 billion or $1.60 per share compared to the prior-year period. After adjusting for certain...

Merck is hell-bent on becoming a major player in the lucrative immune-oncology space as its blockbuster cancer drug Keytruda met its goal of extending the lifespan of cancer patients. https://news.alphastreet.com/merck-sets-the-bar-high-for-rivals-with-positive-keytruda-trial-results/

http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and Juno) multi-billion dollar acquisitions help the struggling Celgene in 2018 and beyond?

It's an M&A Monday for the pharma companies. Two major pharma acquisitions announced today. 1) Celgene acquires Juno for $9 billion http://alph.st/pd7bf702 2) Sanofi acquires Bioverative for $11.6 billion Last week, there was a rumor that Celgene's acquisition of Juno and also news about...

Yesterday, WSJ has stated that Celgene is holding talks to acquire Juno Therapeutics. http://alph.st/pd7bf702 Will this move strengthen Celgene? In 2018, the first acquisition was Impact and now the unconfirmed Juno hunting.

Celgene strengthens its cancer portfolio by acquiring Impact Biomedicines. After stopping the Crohn's disease treatment trials and cutting down the 2020 outlook recently, this deal is a positive news for Celgene. But Sanofi had sold the rights of fedrantinib to Impact in 2016 when the drug was...

A trial testing Revlimid on follicular lymphoma did not meet the desired endpoint. Biogen's RITUXAN also fails..

Celgene announces positive results from the trials with its development partners Bluebird Bio and Juno Therapeutics in ASH 2017. I think it's an advantage for all the three companies involved; especially for Bluebird Bio.

Hello, my colleagues and I at Columbia University are collecting data on cancer clinical trials to better understand the needs of the healthcare community. Please respond to the below questions and thank you in advance for taking the time to complete this questionnaire...